Yonhap Infomax NewsJan 15
Samjin Pharmaceutical is advancing the technology transfer of its chronic urticaria drug candidate SJN314, valued at 800 billion won ($610 million), with expectations for a share price revaluation and a strategic shift from generics to innovative drugs.
#YonhapInfomax
#SamjinPharmaceutical #SJN314 #TechnologyTransfer #ChronicUrticaria #ADCPlatform
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100156
Samjin Pharmaceutical Pursues Technology Transfer Valued at 800 Billion Won—Shares Poised for Revaluation

Samjin Pharmaceutical is advancing the technology transfer of its chronic urticaria drug candidate SJN314, valued at 800 billion won ($610 million), with expectations for a share price revaluation and a strategic shift from generics to innovative drugs.

Yonhap Infomax
Yonhap Infomax NewsNov 14
ABL Bio shares jumped over 10% after announcing a paid-in capital increase targeting Eli Lilly, following a $2.6 billion ADC platform licensing deal, signaling strengthened partnership and investor confidence.
#YonhapInfomax #ABLBio #EliLilly #PaidInCapitalIncrease #TechnologyTransfer #ADCPlatform #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90894
ABL Bio Shares Surge on Decision for Paid-In Capital Increase Targeting Eli Lilly

ABL Bio shares jumped over 10% after announcing a paid-in capital increase targeting Eli Lilly, following a $2.6 billion ADC platform licensing deal, signaling strengthened partnership and investor confidence.

Yonhap Infomax